Biotech News
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly after PPD pivotal program —
